Eli Lilly and Company $LLY Shares Sold by Samalin Investment Counsel LLC

Key Points

• Samalin Investment Counsel LLC reduced its stake in Eli Lilly by 44.1% in the 1st quarter, now holding 1,451 shares valued at approximately $1.2 million.
• Eli Lilly reported a strong quarterly earnings result with $6.31 EPS, exceeding estimates and showing a 37.6% revenue growth compared to the previous year.
• The company declared a quarterly dividend of $1.50 per share, with an annual yield of 0.9%, to be paid on September 10th.

Samalin Investment Counsel LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 44.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,451 shares of the company's stock after selling 1,146 shares during the quarter. Samalin Investment Counsel LLC's holdings in Eli Lilly and Company were worth $1,199,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of LLY. WestEnd Advisors LLC lifted its stake in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares during the period. Citizens National Bank Trust Department grew its stake in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $40,000. Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company in the 4th quarter valued at $43,000. Finally, O Brien Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jamere Jackson bought 200 shares of Eli Lilly and Company stock in a transaction dated Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Down 0.3%

Shares of NYSE LLY traded down $1.92 during midday trading on Thursday, hitting $732.25. 3,113,626 shares of the company's stock were exchanged, compared to its average volume of 7,030,230. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $969.65. The company has a market cap of $693.05 billion, a PE ratio of 47.86, a P/E/G ratio of 1.02 and a beta of 0.44. The firm's fifty day simple moving average is $750.34 and its 200-day simple moving average is $787.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the company earned $3.92 EPS. The business's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on LLY shares. HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and raised their target price for the stock from $675.00 to $700.00 in a research note on Wednesday. Guggenheim lowered their price target on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a report on Wednesday, August 13th. Daiwa Capital Markets lowered Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price on the stock. in a research note on Sunday, August 17th. Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $950.17.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.